IMC-001(Immunofoco)

N/A

Report date: 2025/03/21 17:12:11

Base Information

Drug NameIMC-001(Immunofoco)
Drug Alias NameIMC-001IMC001
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-EpCAMImmunologic cytotoxicityT lymphocyte replacements
TargetsEpithelial cell adhesion molecule
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsGastroenteropancreatic neuroendocrine tumorSolid tumours +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth KoreaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSuzhou Immunofoco Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesChengdu Yimufeng Biotechnology Co LtdSuzhou Immunofoco Biotechnology Co LtdImmuneoncia Therapeutics Inc +[4] 
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsGastroenteropancreatic neuroendocrine tumorSolid tumours +[13] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A